Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,877,600.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 40,000 shares of the company’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the sale, the chief executive officer owned 695,686 shares in the company, valued at approximately $50,047,650.84. This trade represents a 5.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Neil Kumar also recently made the following trade(s):

• On Thursday, January 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $73.97, for a total value of $2,958,800.00.
• On Monday, December 15th, Neil Kumar sold 30,011 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.64, for a total transaction of $2,240,021.04.
• On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.40, for a total transaction of $2,976,000.00.
• On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The stock was sold at an average price of $65.84, for a total transaction of $1,722,111.04.

BridgeBio Pharma Trading Down 1.1%

Shares of NASDAQ:BBIO opened at $75.25 on Friday. BridgeBio Pharma, Inc. has a 52 week low of $28.33 and a 52 week high of $84.94. The company’s 50 day moving average is $75.60 and its two-hundred day moving average is $63.20. The company has a market cap of $14.50 billion, a PE ratio of -18.00 and a beta of 1.13.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently modified their holdings of the business. Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma during the 1st quarter worth $35,000. KLP Kapitalforvaltning AS grew its holdings in shares of BridgeBio Pharma by 20.1% during the second quarter. KLP Kapitalforvaltning AS now owns 28,035 shares of the company’s stock worth $1,211,000 after buying an additional 4,700 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in BridgeBio Pharma in the 2nd quarter valued at about $424,000. Vanguard Personalized Indexing Management LLC raised its stake in BridgeBio Pharma by 5.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 16,178 shares of the company’s stock valued at $699,000 after acquiring an additional 772 shares during the last quarter. Finally, CWM LLC raised its stake in BridgeBio Pharma by 29.8% during the 2nd quarter. CWM LLC now owns 6,830 shares of the company’s stock valued at $295,000 after acquiring an additional 1,569 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a report on Friday, November 7th. TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Wells Fargo & Company raised their price objective on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday. Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday. Finally, Piper Sandler increased their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.55.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.